Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trisacryl gelatin microspheres are precisely calibrated, spherical, nonresorbable embolic particles composed of a trisacryl polymer core cross-linked with gelatin. They are hydrophilic, compressible, and designed for use in therapeutic embolization procedures. Upon administration via catheter into the vascular system, these microspheres occlude blood vessels by physically blocking blood flow to targeted tissues such as tumors or arteriovenous malformations (AVMs). Their uniform size allows for controlled and predictable embolization outcomes. Trisacryl gelatin microspheres can also serve as drug delivery vehicles when loaded with therapeutic agents for localized treatment during embolization[1][4][6]. Primary indications include preoperative devascularization of highly vascularized tumors and the treatment of AVMs in various anatomical locations including the uterus (e.g., uterine fibroid embolization), head, neck, spine, and other sites[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trisacryl gelatin microspheres.